Nexalin Share Price

Nexalin Share Price

NASDAQ: NXL | Micro Cap | Healthcare
$1.36
+$1.36 (--%) Last updated on 21 Nov, 2026 | 02:02 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Nexalin Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
$0.30 - $10.88
Volume
N/A
Average Traded
N/A

Nexalin Share Price Chart

Line chart of the Nexalin price trend over the selected period. The price rose overall, ranging from 1.34 to 1.36, ending at 1.36.
$0.00$0.00
L
Show Current Price
H

Nexalin Stock Fundamentals & Key Indicators

Market Cap
$22.29M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-7.58
Revenue (TTM)
$300.00M
Return On Equity (TTM)
-3559.47%
Profit Margin
-2740.00%
Debt to Equity
3.62
Quarterly Earnings Growth YoY
-11.76%

Nexalin Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.17$0.01$0.01$0.08
Net Profit-$2.38-$2.10-$2.24-$2.66
Net Profit Margin-1400.00%-21000.00%-22400.00%-3325.00%
Income ChangeN/A11.76%-6.67%-18.75%

Nexalin Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$1.32$0.11$0.17$0.30
Net Profit-$1.70-$4.65-$7.61-$8.22
Net Profit Margin-128.79%-4227.27%-4476.47%-2740.00%
Income ChangeN/A-173.53%-63.66%-8.02%

Nexalin Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets0.340.260.20.01
Current Assets4.33.963.437.43
Total Assets4.644.223.637.43
Non Current Liabilities0.00.00.00.0
Current Liabilities0.890.550.431.95
Total Liabilities0.890.550.431.95
Shareholders' Equity3.753.683.215.48

Nexalin Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-4.96-3.94-3.84-2.22
Investing-0.13-0.584.45-6.79
Financing5.174.52-0.28.51

Corporate Actions

Split
Ex-date: 31 Aug 2026

About Nexalin

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Nexalin Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$1.53
$1.54
+1.99%
Oct 2026
$8.58
$1.51
-71.24%
Sep 2026
$5.47
$5.25
+1,615.69%
Aug 2026
$0.33
$0.31
-15.00%
Jul 2026
$0.35
$0.36
+7.14%
Jun 2026
$0.61
$0.34
-44.28%
May 2026
$0.38
$0.60
+74.78%
Apr 2026
$0.36
$0.34
-1.99%
Mar 2026
$0.47
$0.35
-25.11%
Feb 2026
$0.56
$0.47
-16.07%
Jan 2026
$0.64
$0.56
+0.00%
Dec 2025
$0.97
$0.56
-48.15%

Nexalin Share Price FAQs